Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure

NCT01102790

Heparin-Induced Thrombocytopenia Thrombosis

UNKNOWN

Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

NCT05783895

Heparin-induced Thrombocytopenia

UNKNOWN

A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients

NCT00198575

Heparin-Induced Thrombocytopenia

UNKNOWN

Fibrinogen in Liver Transplant

NCT07265843

Liver Transplant Surgery

NOT_YET_RECRUITING PHASE4

Fibrinogen in Liver Transplant Subjects

NCT06764927

Liver Transplant Surgery

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators examined the frequency of anti-PF4/heparin antibodies (IgG/M/A; EIA) and their functional activity (HIPA) in 38 whole organ deceased donor liver transplant recipients. Additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (ALAT, ASAT, cholinesterase) were investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heparin-induced Thrombocytopenia Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

orthotopic Liver Transplantation

consecutive inclusion of all recipients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all consecutive liver transplant recipients between 01/2010 and 08/2011 who
* were transplanted at our center after allocation of a liver graft via Eurotransplant